CHARACTERISTICS OF PROLIFERATIVE DIABETIC RETINOPATHY IN LE VAN THINH HOSPITAL
Main Article Content
Abstract
Objectives: Describe the characteristics of proliferative diabetic retinopathy in Le Van Thinh Hospital. Methods: The cross-sectional descriptive study was conducted on 32 patients with type 2 diabetes from December 2023 to August 2024. Results: The mean age is 59,69 ± 10,61 years. The mean duration of diabetes mellitus diagnosis is 7,15 ± 4,84 years (2 – 20 years). The proportion of patients checking blood sugar monthly in diabetes treatment is 93,8%, and irregular is 6,3%. The mean blood glucose level (HbA1C) is 7,55 ± 1,72% (5,3% to 13,2%). The mean number of years diagnosed with diabetic retinopathy is 3,62 ± 1,60 years (1 to 8 years). The mean logMAR visual acuity (VA) is 0,74 ± 0,68 (Snellen equivalent 6/30). The proportion of patients with good VA > 7/10 (20/30) is 12,5%, the moderate low VA group 4/10 - 7/10 (20/50 - 20/30) is 31,3%, and low VA group ≥ 3m – 3/10 (20/70) accounts for the highest proportion with 37,5%, near-blind group: counting finger (CF) < 3m is 18,8%. The rate of macular edema is 79,17% (38/48 eyes). The mean central macular thickness (CMT) is 326,44 ± 99,73 µm. The mean macular volume is 7,91 ± 1,56 mm3. The mean foveal avascular zone (FAZ) area is 0,281 ± 0,09 mm2. Vascular density (VD) in the superficial capillary plexus (SCP) in the parafovea area has the highest mean value (41,01 ± 5,17%), and the foveal area has the lowest value (14,88 ± 3,94%). There is no significant association between visual acuity and central macular thickness, macular volume, foveal avascular area, and superficial layer vascular density (p > 0,05). Conclusion: Proliferative diabetic retinopathy seriously affects the vision of diabetic patients.
Article Details
Keywords
Diabetes mellitus, diabetic retinopathy, proliferative diabetic retinopathy.
References
2. Đỗ Như Hơn (2014), “Bệnh lý võng mạc đái tháo đường”, Nhãn khoa tập 3. Nhà xuất bản y học, 268-285.
3. Jose Cunha-Vaz (2011), “Diabetic Retinopathy”, World Scientific.
4. The ETDRS Research Group, Barton F., Fisher M., Kinyoun J., et al (1989), “Detection of diabetic macular edema. Ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5”, Ophthalmology.96(6), 746-750.
5. Ayman G Elnahry, et al (2022), “Optical Coherence Tomography Angiography Biomarkers Predict Anatomical Response to Bevacizumab in Diabetic Macular Edema”, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022:15 395–405
6. Abdelhalim A S, et al (2022), “Macular vessel density before and after panretinal photocoagulation in patients with proliferative diabetic retinopathy,” International Journal of Retina and Vitreous. (2022) 8:21
7. Nguyễn Đình Ngân (2020), “Đánh giá hiệu quả tiêm nội nhãn bevacizumab điều trị phù hoàng điểm do đái tháo đường tại Bệnh viện Quân y 103”, Tạp chí Y dược lâm sàng 108. Tập 15 – số 2/2020, tr.111-118.
8. Trần thị Thu Hiền, Dương Anh Quân (2016), “Đánh giá kết quả điều trị bệnh võng mạc đái tháo đường bằng tiêm Bevacizumab nội nhãn”, Tạp Chí Y Học Lâm Sàng.số 35/2016.
9. Phạm Diệu Linh và cộng sự (2023), “Mô tả đặc điểm lâm sàng bệnh võng mạc đái tháo đường tại bệnh viện E trung ương”, Tạp Chí Y Học Việt Nam. Tập 530 - số 2/2023.